Article
Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer.
Human vaccines & immunotherapeutics - 31 Dec 2024
Dailey Gabrielle P, Rabiola Christopher A, Lei Gangjun, Wei Junping, Yang Xiao-Yi, Wang Tao, Liu Cong-Xiao, Gajda Melissa, Hobeika Amy C, Summers Amanda, Marek Robert D, Morse Michael A, Lyerly Herbert K, Crosby Erika J, Hartman Zachary C
Abstract excerpt
ER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, which can occur through the emergence of gain-of-function mutations in ESR1. The central importance of ESR1 and development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.